Merck & Co., Inc. (NYSE:MRK) Cut to "Strong Sell" at Zacks Research

Key Points

• Zacks Research downgraded Merck to “strong sell” from “hold,” although the broader analyst consensus remains “Moderate Buy,” with 17 Buy, nine Hold and one Sell rating and an average price target of $151.92.
• Merck shares traded up 3.2% to $148.19, near their 52-week high, after the company exceeded quarterly earnings and revenue expectations; fiscal 2026 EPS guidance is $2.66–$2.76.
• Keytruda concentration and the approaching patent cliff remain major risks, increasing pressure on newer cancer treatments to become meaningful growth drivers. Insiders sold roughly $30 million of stock over the past quarter.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a report issued on Monday, Zacks reports.

Several other analysts have also commented on the stock. Argus raised their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an "overweight" rating in a research note on Monday, October 5th. HSBC lifted their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a "buy" rating in a report on Thursday, September 10th. Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a report on Friday, September 4th. Finally, Guggenheim upped their target price on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Seventeen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average target price of $151.92.

Merck & Co., Inc. Trading Up 3.2%

MRK stock opened at $148.19 on Monday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The company's 50 day moving average price is $146.22 and its two-hundred day moving average price is $129.67. The company has a market capitalization of $365.62 billion, a PE ratio of 118.55, a price-to-earnings-growth ratio of 6.64 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business's revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David R. Maraldo sold 18,706 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company's stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 over the last quarter. Corporate insiders own 0.17% of the company's stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds have recently made changes to their positions in the company. Round Rock Advisors LLC raised its holdings in Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock worth $1,272,000 after purchasing an additional 66 shares during the last quarter. Cascade Financial Partners LLC lifted its holdings in Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after purchasing an additional 80 shares in the last quarter. Somerset Trust Co lifted its stake in shares of Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after buying an additional 81 shares during the period. Stonebridge Financial Group LLC lifted its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock worth $1,124,000 after purchasing an additional 81 shares during the period. Finally, Stronghold Wealth Management L.L.C. lifted its position in Merck & Co., Inc. by 2.6% during the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock worth $416,000 after buying an additional 82 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.